Hemicentin-2 inhibitors are a class of chemical compounds specifically designed to target and reduce the activity of hemicentin-2, a protein that plays a significant role in cellular adhesion, migration, and tissue integrity. Hemicentin-2, also known as fibulin-6, is involved in various physiological processes, including the maintenance of extracellular matrix (ECM) composition and the modulation of cell-matrix interactions, crucial for tissue repair, development, and disease progression. The rationale behind the development of hemicentin-2 inhibitors stems from the protein's implicated involvement in pathological conditions, such as fibrosis and certain types of cancer, where its overexpression or dysregulated activity contributes to disease pathology. The initial phase in the discovery of hemicentin-2 inhibitors involves the application of high-throughput screening (HTS) techniques, which enable the identification of molecules capable of specifically binding to and inhibiting hemicentin-2's function. This screening is designed to isolate compounds that can interfere with hemicentin-2's ability to interact with other ECM components or cell surface receptors, thereby modulating its role in cell adhesion, migration, and ECM organization.
Following the identification of potential inhibitors through HTS, the next crucial step involves structure-activity relationship (SAR) studies aimed at optimizing these compounds for increased specificity, potency, and favorable pharmacokinetic properties. SAR studies entail systematic modifications to the chemical structures of the identified inhibitors, assessing how these changes influence their efficacy in inhibiting hemicentin-2. This iterative process is fundamental for enhancing the molecular interaction between the inhibitors and hemicentin-2, ensuring that the compounds are effective in selectively targeting hemicentin-2 with minimal off-target effects. Advanced structural biology techniques, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to gain insights into the precise molecular interactions between hemicentin-2 and the inhibitors, guiding the rational design of more potent inhibitors. Additionally, cellular assays are utilized to assess the functional impact of these inhibitors within a biological context, confirming their ability to disrupt hemicentin-2-mediated cellular processes. Through a comprehensive approach that combines targeted chemical synthesis, detailed structural analysis, and functional validation, hemicentin-2 inhibitors are developed to modulate the activity of hemicentin-2 precisely.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
A broad-spectrum matrix metalloproteinase inhibitor, may indirectly influence Hemicentin-2 by affecting the extracellular matrix. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
An integrin antagonist, could indirectly impact Hemicentin-2 by altering cell adhesion dynamics. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $179.00 $377.00 | 24 | |
Another matrix metalloproteinase inhibitor, potentially affects extracellular matrix remodeling and Hemicentin-2 activity. | ||||||
NSC 405020 | 7497-07-6 | sc-477738 | 10 mg | $105.00 | ||
A specific integrin antagonist, potentially affecting cell adhesion mechanisms relevant to Hemicentin-2. | ||||||
TAPI-1 | 171235-71-5 | sc-222337 | 1 mg | $669.00 | 15 | |
Inhibits ADAM (a disintegrin and metalloproteinase) family, potentially impacting cell adhesion and Hemicentin-2. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
A broad-spectrum matrix metalloproteinase inhibitor, may affect extracellular matrix dynamics influencing Hemicentin-2. | ||||||
SB-3CT | 292605-14-2 | sc-205847 sc-205847A | 1 mg 5 mg | $102.00 $388.00 | 15 | |
A selective inhibitor of matrix metalloproteinase-2 and -9, could indirectly impact Hemicentin-2 function. | ||||||